RESUMEN
SETTING: The northern circumpolar jurisdictions Canada (Northwest Territories, Nunavik, Nunavut, Yukon), Finland, Greenland, Norway, Russian Federation (Arkhangelsk), Sweden and the United States (Alaska). OBJECTIVE: To describe and compare demographic, clinical and laboratory characteristics, including drug resistance and treatment completion, of tuberculosis (TB) cases in the northern circumpolar populations. DESIGN: Descriptive analysis of all active TB cases reported from 2006 to 2012 for incidence rate (IR), age and sex distribution, sputum smear and diagnostic site characteristics, drug resistance and treatment completion rates. RESULTS: The annual IR of TB disease ranged from a low of 4.3 per 100 000 population in Northern Sweden to a high of 199.5/100 000 in Nunavik, QC, Canada. For all jurisdictions, IR was higher for males than for females. Yukon had the highest proportion of new cases compared with retreatment cases (96.6%). Alaska reported the highest percentage of laboratory-confirmed cases (87.4%). Smear-positive pulmonary cases ranged from 25.8% to 65.2%. Multidrug-resistant cases ranged from 0% (Northern Canada) to 46.3% (Arkhangelsk). Treatment outcome data, available up to 2011, demonstrated >80% treatment completion for four of the 10 jurisdictions. CONCLUSION: TB remains a serious public health issue in the circumpolar regions. Surveillance data contribute toward a better understanding and improved control of TB in the north.
Asunto(s)
Antituberculosos/uso terapéutico , Esputo/microbiología , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Regiones Árticas/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Salud Pública , Retratamiento/estadística & datos numéricos , Distribución por Sexo , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Adulto JovenRESUMEN
BACKGROUND: Human immunodeficiency virus (HIV) continues to be a global public health concern, with 2.1 million people newly infected in 2015. Although many high-income countries have noted decreasing rates of HIV, between 2013 and 2015 Canada's rates had stabilized at 5.8 per 100,000 population. OBJECTIVE: To provide a descriptive overview of reported cases of HIV in Canada up until 2016 by geographic location, sex, age group, exposure category and race/ethnicity, with a focus on the most recent data. METHODS: The Public Health Agency of Canada (PHAC) monitors HIV through the national HIV/AIDS Surveillance System (HASS), Immigration, Refugees and Citizenship Canada (IRCC), and the Canadian Perinatal HIV Surveillance Program (CPHSP). HASS is a passive, case-based system that collates non-nominal data voluntarily submitted by all Canadian provinces and territories. Data were also received from the IRCC and the CPHSP. Data were collated, tables and figures were prepared, then descriptive statistics were applied by PHAC and validated by each province and territory. RESULTS: A total of 2,344 new diagnoses of HIV were reported in 2016 in Canada, with a cumulative total of 84,409 cases since 1985. The national diagnosis rate increased from 5.8 per 100,000 population in 2015 to 6.4 per 100,000 population in 2016. Saskatchewan reported the highest provincial diagnosis rate in 2016 (15.1 per 100,000 population). In 2016, 76.6% of reported HIV cases were among males. Adults aged 30-39 years old accounted for 28.7% of all reported cases. There was a similar age distribution of HIV cases between sexes with notable increases in the proportion of the 50 years and over age group over the past five years. The "men who have sex with men" exposure category continued to represent the largest number and proportion of all reported HIV cases in adults (44.1%). White (40.4%), Black (21.9%) and Indigenous (21.2%) race/ethnicity categories represented the largest proportions of cases. CONCLUSION: In 2016, Canada saw a slight increase in the number and rate of reported HIV cases compared with previous years. Although the diagnostic rate was lower than in all years prior to 2012, it is the highest of the past five years. While a number of possibilities exist to explain this increase, further investigation and additional data are needed in order to determine the cause and significance.
RESUMEN
BACKGROUND: Although there continues to be a global epidemic of people living with human immunodeficiency virus (HIV) there has been a decrease in the number of people dying of acquired immunodeficiency syndrome (AIDS), largely due to successful treatment with antiretroviral therapy. OBJECTIVE: To provide a descriptive overview of the reported cases of AIDS in Canada by identifying trends by geographic location, sex, age group and mortality. While the descriptive analysis focuses on the year 2016, results are presented for reported cases from the beginning of national AIDS surveillance in 1979. METHODS: The Public Health Agency of Canada (PHAC) monitors AIDS in Canada through the national HIV/AIDS Surveillance System (HASS) and Statistics Canada. HASS is a passive, case-based surveillance system that maintains non-nominal data on cases of HIV and AIDS provided voluntarily by the Canadian provinces and territories. Of note, AIDS is no longer a reportable disease in Newfoundland and Labrador (as of 2009) and in Prince Edward Island (as of 2012). Data were also retrieved on annual deaths attributed to HIV/AIDS from Statistics Canada. Data were collated, tables and figures were prepared, then descriptive statistics were applied by PHAC and validated by each province and territory. RESULTS: A total of 114 AIDS cases were reported in 2016, with a cumulative total of 24,179 since 1979. These numbers represent a steady decline in the number of reported AIDS cases per year of diagnosis in Canada since 1993. Of reporting provinces, the greatest numbers of cases in 2016 were reported by Ontario, Saskatchewan and Alberta. Males accounted for 72.8% of reported AIDS cases and adults aged 50 years and older accounted for the greatest proportion by age group (36.0%). For all reporting years combined, the age distribution of AIDS cases is similar by sex, though a larger proportion of female cases were under the age of 30 years old. Limited data were reported for ethnicity and risk factors. The numbers of annual deaths attributed to AIDS infection have been declining since 1995. There were a record low of 241 AIDS-related deaths reported in 2013-the most recent year for which data were available. The number of AIDS-related deaths in Canada has declined 86.2% since 1995. CONCLUSION: The number of AIDS cases reported by participating provinces and territories and the number of AIDS-related deaths reported by Statistics Canada has declined. While this represents a promising trend, the data should be interpreted with caution given the limitations of the dataset which could lead to an underestimate of the magnitude of the disease.
RESUMEN
BACKGROUND: Drug-resistant strains of tuberculosis (TB) pose a serious threat to prevention and control efforts. In response to this growing worldwide concern, the Public Health Agency of Canada (PHAC) established and maintains the Canadian Tuberculosis Laboratory Surveillance System (CTBLSS) in partnership with the Canadian Tuberculosis Laboratory Technical Network (CTLTN) and participating laboratories. OBJECTIVE: To report on national trends and patterns in anti-tuberculosis drug resistance in Canada for the years 2003 to 2013. METHOD: At the beginning of each calendar year, participating laboratories submit to PHAC reports on the results of anti-tuberculosis drug susceptibility testing for all isolates tested during the preceding year. These data are then analyzed by PHAC and the results are validated by supplying laboratories. The results are published annually as the Tuberculosis Drug Resistance in Canada series. RESULTS: In 2013, anti-tuberculosis drug susceptibility test results for 1,380 isolates were reported to PHAC. Of these, 762 (54%) were reported as Mycobacterium tuberculosis complex (MTBC) where the species was known. Two thirds (68%) of all the reported isolates originated from the three largest provinces, British Columbia, Ontario and Quebec. Overall, of the laboratory results received, 112 (8.1%) showed resistance to at least one first-line drug and, of these, the majority (93 or 83%) were monoresistant. CONCLUSION: TB drug resistance observed in Canada remains well below the global average. Over the last 10 years, the percentage of isolates with resistance to one or more of the first-line medications has decreased from 10.5% in 2003 to 8.1% in 2013.
RESUMEN
Effective contact investigations are paramount to the success of tuberculosis (TB) control in high-risk communities in low TB prevalence countries. National and international guidelines on TB contact investigations are available and vary widely on recommendations. Because of the limitations of traditional contact tracing, new approaches are under investigation, and in some cases in use, to ensure effective TB control in those persons and communities at greatest risk. These non-traditional approaches include the use of social network analysis, geographic information systems and genomics, in addition to the widespread use of genotyping, to better understand TB transmission. Detailed guidelines for the use of these methods during TB outbreaks and in routine follow-up of TB contact investigations do not currently exist despite evidence that they may improve TB control efforts. It remains unclear as to when it is most appropriate and effective to use a network-informed approach alone, or in combination with other methodologies as well as the extent of data collection required to inform practice. TB controllers should consider developing the capacity to facilitate the systematic collection, analysis, and interpretation of contact investigation data using such novel methodologies, particularly in high-risk communities. Further investigation should focus on questionnaire development and adaptation, electronic data management and infrastructure, development of local capability and consultant expertise, and the use of coordinated approaches, including deployment strategies and evaluation.